Efficacy and safety of ormeloxifene, a selective estrogen receptor modulator in management of dysfunctional uterine bleeding in perimenopausal patients: a prospective interventional study

Authors

  • Namita Shrivastava Jankikund Chikitsalaya, Chitrakoot, Madhya Pradesh, India
  • Ritu Rani Vivekanand Polyclinic and Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20233620

Keywords:

Ormeloxifene, Dysfunctional uterine bleeding, PBAC, Selective estrogen receptor modulator

Abstract

Background: Dysfunctional uterine bleeding (DUB) is one of the most common menstrual disorder of women in any age group and is a diagnosis of exclusion. Medical management of menorrhagia is a difficult task as there are wide variations in the available drugs and a lot of different regimes are available. Present study evaluates efficacy and safety of ormeloxifene a selective estrogen receptor modulator (SERMs) in treatment of dysfunctional uterine bleeding in perimenopausal women.

Methods: The study was conducted on 120 patients in the age group of 40-55 years who were treated with 60 mg ormeloxifene twice a week for first 12 weeks and once weekly for next 12 weeks. The primary outcome measures were menstrual blood loss (assessed by pictorial blood assessment chart score), hemoglobin concentration and endometrial thickness. The secondary outcome measures were aceptability and side effects of ormeloxifene.

Results: 86.66% of women showed marked improvement in symptoms. Mean endometrial thickness decreased significantly from 9.825 mm to 6.25 mm after 6 months of treatment (p value <0.001). A significant decrease in median PBAC score (p value <0.001) was observed. Also, the mean haemoglobin level increased significantly from 8.03 g/dl to 9.60 g/dl (p value <0.001). Most common side effect reported was amenorrhoea (16%). 4% patient not relieved underwent hysterectomy.

Conclusions: Ormeloxifene could be the drug of choice in patients with DUB. It is safe, cost-effective with manageable side effects. The therapy has facilitated compliance, tolerability and reduction of symptoms resulting in adherence towards the treatment.

References

Padubidri VG, Shirish D. Hawkins and Bourne Shaw’s Textbook of Gynaecology, Menorrhagia and Dysfunctional Uterine Bleeding. 15th edition. Elsevier (Publishers). 2018;153-61.

Vaidya R, Vinayachandran S, Devi S, Prejisha B, Lekshminath G, Sreedharan S, et al. Prevalence of Abnormal Uterine Bleeding and its Associated Risk Factors in Women of Perimenopausal Age Group- A Retrospective Study. J Clin Diagnost Res. 2022;16(12):QC09-13.

Bravender T, Emans S. Menstrual Disorders. Dysfunctional Uterine Bleeding. Pediatr Clin North Am. 1999;3(46):545-53.

Dadich S, A, Soni M, Jain R. Role of ormeloxifene in medical management of dysfunctional uterine bleeding. Asian J Obs Gynae Pract. 2012;6:28-31.

Mani A, Sharma K, Kumar A, Talukdar RK. Selective estrogen receptor modulator: efficacy in abnormal uterine bleeding in perimenopausal women. Int J Reprod Contracept Obstet Gynecol. 2019;8(4):1495-9.

Takreem A, Danish N, Razaq S. Incidence of endometrial hyperplasia in 100 cases presenting with polymenorrhagia/menorrhagia in perimenopausal women. J Ayub Med Col Abbottabad. 2009;21:60-3.

Prerna S, Verma A, Verma K. Role of Ormeloxifene in management of abnormaluterine bleeding. Sch J App Med Sci. 2017;5(3B):796-9.

Monteiro I, Bahamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. Contraception. 2002;65(5):325-8.

Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone related clinical disorders. Med Res Rev. 2001;21:302-47.

Council of Scientific & Industrial Research. Ministry of Science & Technology, Govt. of India. Available at: http://www.csir.res.in. Assessed on 12 August 2022.

Nisha K, Prajwala A. Ormeloxifene in the management of AUB. Int J Clin Obstet Gynaecol 2019;3(2);229-30.

Kriplani A, Kulshrestha V, Agarwal N. Efficacy and safety of Ormeloxifene in management of menorrhagia: A pilot study. J Obstet Gynaecol Res. 2009;35:746-52.

Higham JM, O’Brien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97(8):734-9.

Sarbhai V, Kumari S. Ormeloxifene: The Perfect Alternative for the First-line Management of Abnormal Uterine Bleeding. J South Asian Fed Obstet Gynaecol. 2023;15(1):85-7.

Biswas SC, Sah SK, Bag TS, Roy SCG, Roy AC, Kabiraj SP. Ormeloxifene, A selective estrogen receptor modulator for treatment of dysfunctional menorhagia. J Obstet Gynecol. 2004;54(1):56-9.

Dhananjay BS, Nanda SK. The Role of Sevista in the Management of Dysfunctional Uterine Bleeding. J Clin Diagnost Res. 2013:7(1);132-4.

Agarwal N, Singh S. The efficiency and safety of ormeloxifene in dysfunctional uterine bleeding. IOSR J Pharm Biolog Sci. 2013;5(5):18-21.

Bhattacharyya TK, Banerji. A. Efficiency of a selective estrogen receptor modulator ormeloxifene in management of dysfunctional uterine bleeding. South Asian Feder Obstet Gynaecol. 2010;2:207-11.

Downloads

Published

2023-11-28

Issue

Section

Original Research Articles